top of page

NICE recommends ataluren for Duchenne muscular dystrophy

The UK National institute for Health and Care Excellence (NICE) has recommended PTC Therapeutics’ Translarna (ataluren) for treating children aged 5 and over with Duchenne muscular dystrophy (DMD) caused by a nonsense mutation. Commenting on the recommendation, Sir Andrew Dillon, chief executive of NICE, said: “Duchenne muscular dystrophy caused by a nonsense mutation is a cruel disease that currently has few treatment options. Ataluren is a medicine that for the first time is aimed at the root cause of the disease and has the potential to offer benefits to people with the condition and their families.”

Click on this link for more information.



Today's News
Follow us
  • LinkedIn Social Icon
  • Vimeo Social Icon
Newsletter on Pharma Legislation
the newsletter of
bottom of page